Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cetuximab + THOR-707 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 58 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
THOR-707 | THOR707|THOR 707|SAR444245|SAR-444245|SAR 444245 | THOR-707 is a pegylated recombinant version of IL-2 that binds IL2beta, but does not bind to IL-2 alpha, potentially resulting in activation and tumor infiltration of CD8-positive T cells without proliferation of CD4-positive immune cells (Annals of Oncology (2019) 30 (suppl_5): v475-v532). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05104567 | Phase II | Cetuximab + THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | Terminated | USA | NLD | ITA | FRA | ESP | BEL | 3 |
NCT05061420 | Phase II | Cetuximab + Pembrolizumab + THOR-707 Cetuximab + THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) | Active, not recruiting | USA | NLD | ITA | FRA | ESP | DEU | CAN | 4 |